Eye Care Insider

In this podcast, Joshua Mali, MD, brings you the best insights and perspectives in the field of eye care today. Through interviews with thought leaders in ophthalmology, Mali gets the inside of every story.

Corneal Rejuvenation with Trefoil Therapeutics 05/01/2023

Corneal Rejuvenation with Trefoil Therapeutics In this episode, I discuss corneal disease and treatments with David Eveleth, PhD, the founder, president and CEO of Trefoil Therapeutics. Brought to you by Alcon · Welcome to another exciting episode of Eye Care insider :14 · Intro David Eveleth, PhD :47 · Eveleth’s background 1:05 · What’s the treatment landscape now for corneal diseases and where are we falling short for patients? 2:59 · The origins of Trefoil Therapeutics 7:27 · FGF-1: Is it just important in the endothelium or is it also important in the epithelium? 11:47 · What is your current lead investigational candidate? 14:01 · When do you expect another read out of clinical data? 21:47 · An adjunctive therapy with cataract surgery 18:27 · What is the timeline of administration to patients? 19:24 · When do you expect a readout of clinical data? 20:49 · Is it possible to use this also for the epithelium? 21:39 · What are the most important challenges facing the ophthalmic industry? What is the most important factor to look for? 24:07 · For more information about David Eveleth, PhD, and Trefoil Therapeutics, visit 25:53 · Corneal disease can be fixed and better vision is possible 26:44 · Thanks for listening 27:04 We’d love to hear from you! Send your comments/questions to Dr. Mali at . Follow us on Twitter . You can find follow Trefoil Therapeutics on Twitter @TrefoilThera. David Eveleth, PhD, is the president and CEO of Trefoil Therapeutics. Disclosures: Eveleth is the founder, CEO and shareholder of Trefoil Therapeutics. Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; consultant/speaker for Genentech and Roche; equity owner for SNAPS; and grant/consultant for RetinAI. /episode/index/show/eyecareinsider/id/26705091

EyePoint Pharmaceuticals’ EYP-1901: Promising Novel Drug Delivery System 04/07/2023

Samsara Vision’s SING IMT: Game Changer for the Advanced AMD Patient 03/21/2023

Dr. Mali's Top 5 Predictions in Ophthalmology for 2023 01/04/2023

What Ophthalmologists Are Thankful For: Dr. Mali’s Top 5 Greatest Innovations Of The 21st Century in Ophthalmology 11/21/2022

Dr. Mali's AAO 2022 Annual Meeting Hot Topics Post Meeting Reaction 10/18/2022

Dr. Mali’s AAO 2022 Annual Meeting Hot Topics Preview 09/27/2022

Financial Pearls for the Eye Care Professional 2022 08/23/2022

Financial Pearls for the Eye Care Professional 2022 In this episode, Jose O. Segura, wealth management advisor and certified business exit planner, discusses establishing objectives within financial planning and organization, how to diversify your portfolio in ever-changing markets and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Jose Segura 1:03 For people that are listening for the first time, do you mind giving a brief of your background? 1:32 What are, in your opinion, some best practices in regard to financial planning? 2:58 Process for financial organization and seeking out advisors. 10:09 Can you talk about the importance of portfolio diversification? 12:07 Importance of maintaining your overall focus on financial planning and strategies when markets are effected. 16:56 Could you give us one pearl for our listeners, or one key economic update that you think would be really important to the current economic situation right now? 18:49 Thank you Jose 23:09 Any final words to our listeners? 23:11 Outro 23:35 Jose O. Segura, is a wealth management advisor and certified business exit planner. We’d love to hear from you! Send your comments/questions to Dr. Mali at . Follow us on Twitter . For more information about Segura, visit , reach him by email at , or call 518-867-3210 x104. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Segura reports he is a registered Representative and Financial Advisor of Park Avenue Securities LLC (PAS), 355 Lexington Avenue, 9 Fl., New York, NY 10017, 212-541-8800. /episode/index/show/eyecareinsider/id/24144699

Virtual Reality in Ophthalmology: The New Frontier with Ashlie Leal 08/09/2022

Virtual Reality in Ophthalmology: The New Frontier with Ashlie Leal In this episode, Ashlie Leal, director of ophthalmology at FundamentalVR, discusses their fully immersive surgical training products, how virtual reality plays a role in training surgeons and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Ashlie Leal 1:00 Give me a little bit of your background – how you got into this industry and your role at FundamentalVR? 1:33 Can you give our listeners some background about FundamentalVR as a company, and why should eye care professionals start paying attention to your company? 2:56 Do you target training programs? … Is there a certain focus to your company in regards to demographics? 4:12 Is there any way you can describe [your virtual reality products] or any current product offers that you have that apply to eye care professionals? 7:30 You’re using a headset and the two arms. Is that all you would need, or would you need some sort of base mannequin head with an eyeball simulation? 9:25 You can do it anywhere, theoretically? And you can simulate different MIGS equipment and different ocular lens implants based on the tech simulating that equipment? 10:59 So, the simulation is able to carry out these multiple, intricate steps? 12:03 Is there current gene therapy that is utilizing your technology? Do you have a relationship with them in the sense that you provide the surgeons with the virtual reality simulations? 12:49 Do you have any sort of data or any procedure done with virtual reality improving complication rate and efficiency? 14:02 What does the future look like for virtual reality? What would you say is the major challenge, or what does your company hope to accomplish in the next few years or the decade? 15:30 What’s that process look like for a company to approach you for virtual reality offering to train on a new device? How long does that process take, and what are the steps to assimilate their product into your technology? 17:14 If someone wants to learn more, how can they contact you or your company for more information? 19:13 Congratulations Ashlie and FundamentalVR 19:39 Any final words to our listeners? 20:02 Outro 20:39 Ashlie Leal is director of ophthalmology, FundamentalVR. We’d love to hear from you! Send your comments/questions to Dr. Mali at . Follow us on Twitter . Leal can be reached on LinkedIn or at . Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Leal reports she is director of ophthalmology at FundamentalVR. /episode/index/show/eyecareinsider/id/24004473

Nanodropper: The Potential Gamechanger with Allisa Song 06/22/2022

Nanodropper: The Potential Gamechanger with Allisa Song In this episode, Allisa Song, a medical student and the CEO and co-founder of Nanodropper, discusses the inception of the device, how it can benefit the eye care industry and more. Intro :38 Welcome to another episode of Eye Care insider :52 About Allisa Song 1:01 I want to hear your story about the history about the Nanodropper – how you came to this idea; what problem you were trying to solve; and how you got here? 2:02 What are the major advantages of your product? Why doesn’t our standard bottle function properly like that? 5:06 Can this go on every eyedrop bottle? 6:49 Is there any sort of data that we can look at that shows how much volume of the prescription is saved? 7:51 Can you talk to me about how industry has taken this? What is your take on how they feel about your product? 12:15 How are you distributing your product to the consumers and to the masses? What are your channels to get the product out there? 15:36 What do you think the future holds for Nanodropper? Where do you see this going in the next 3 to 5 years? 17:04 Is there any information that you can provide to our listeners can go to and learn more about your story? 18:23 Congratulations again Allisa 19:03 You’ll be graduating from medical school pretty soon? 19:15 Any final words to our listeners? 19:50 Outro 20:26 Allisa Song, is a Mayo Clinic Alix School of Medicine medical student and the CEO and co-founder of Nanodropper. Song is a serial entrepreneur and inventor with a background in Clean Tech, neuroscience, and harm reduction. In addition to her proven track record of successful fundraising, she has led her teams to dozens of business and design awards, including her most recent USPTO Collegiate Inventor medal awarded by the National Inventors Hall of Fame. We’d love to hear from you! Send your comments/questions to Dr. Mali at . Follow us on Twitter . Song can be reached at . Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Song is the CEO and co-founder of Nanodropper and serves as an advisor for Bedo Solutions. /episode/index/show/eyecareinsider/id/23507075

OptiLight in the Dry Eye Practice with Arthur Benjamin, MD 05/25/2022

OptiLight in the Dry Eye Practice with Arthur Benjamin, MD In this episode, Arthur Benjamin, MD, discusses dry eye treatment and trends, the challenges dry eye patients and the eye care professionals treating them and more. Intro :37 Welcome to another episode of Eye Care insider :51 About Arthur Benjamin, MD 1:02 I wonder if you could talk about your training and what you currently do now? 1:39 Could you talk about what you’ve seen throughout the years and what you’ve seen in the trends in dry eye and how it has expanded in the population? 2:56 What is your current algorithm for someone with dry eye? How do you manage that? 5:01 Once you do determine they have moderate dry eye where do you start with the patient or the treatment paradigm? 7:00 With the OptiLight treatment option … what do you tell patients? What should they be expecting? 9:54 I recently saw that there’s been a campaign from OptiLight involving Mandy Moore. Could you talk about that campaign and discuss it a little bit further? 12:54 What do you think is the most important topic or issue or challenge that are facing dry eye patients today or eye care professionals treating patients with dry eye? 16:07 What a fascinating discussion 17:43 Any last words? 17:55 Outro 18:09 Arthur Benjamin, MD, is a clinical assistant professor at the Jules Stein/Doheny Eye Institute at UCLA’s Geffen School of Medicine and is in private practice at Benjamin Eye Institute. We’d love to hear from you! Send your comments/questions to Dr. Mali at . Follow us on Twitter . Dr. Benjamin can be contacted by going to BenjaminEye.com. Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Benjamin reports no relevant financial disclosures. /episode/index/show/eyecareinsider/id/23225183

Ocushield: Blue Light Blocking Filters in the Eye Care Practice 04/29/2022

Ocushield: Blue Light Blocking Filters in the Eye Care Practice In this episode, Dhruvin Patel, MCOptom, discusses the short- and long-term effects of blue light on our eyes, how the pandemic has exacerbated these effects and how his company, Ocushield, is looking to help protect eyes from blue light. Intro :01 Patel’s introduction and background :43 The science and necessity behind blue light blocking filters 5:35 Short-term effects of blue light on the eyes 7:15 Long-term effects of blue light on the eyes 8:24 Are eye care professionals doing enough to promote blue light protection? 12:11 Has the pandemic affected the demand/awareness of blue light related products? 14:25 Ocushield filters: what they are and how to get them 16:15 What makes Ocushield unique in the blue light/ophthalmic landscape? 19:03 How to contact Dr. Patel and Ocushield 20:31 Patel’s final thoughts on our visual system and the importance of protecting it 21:11 Outro 22:01 Dhruvin Patel, MCOptom, is an optometrist and the founder of Ocushield. You can send your comments/questions directly to him at . Follow him on Instagram, Facebook and Twitter @getocushield. We’d love to hear from you! Send your comments/questions to Dr. Mali at . Follow us on Twitter Disclosures: Mali reports he is founder and CEO of Mali Enterprises; retina medical director at Macular Degeneration Association; grant/research support from Alimera Sciences, Allergan/AbbVie, Chengdu Kanghong Biotechnology, Genentech, Notal Vision, Regeneron and Santen; consulting for Alimera Sciences, Allergan/AbbVie, Eyepoint Pharmaceuticals, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis, Regeneron and Sun Pharmaceuticals; speaker bureau for Alimera Sciences, Genentech, Kala Pharmaceuticals, Macular Degeneration Association, Notal Vision, Novartis and Sun Pharmaceuticals; and stock/shareholder with AbbVie and Regeneron. Patel is founder of Ocushield. /episode/index/show/eyecareinsider/id/22955135